Find an Oncologist in the U.S. Selector v1.1.2 (2026)

By Editorial Team

Find an Oncologist in the U.S.

Answer seven questions to identify the type of oncology specialist and cancer-center resources that may fit your needs.

Step 1 of 7

What cancer are you dealing with?

Select the cancer type that best matches your diagnosis. If you have not received a diagnosis, choose the last option.

Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Pancreatic cancer
Liver or biliary cancer
Kidney or renal cancer
Ovarian or gynecologic cancer
Brain or CNS cancer
Leukemia, lymphoma or myeloma
Melanoma or skin cancer
Head and neck cancer
Sarcoma
Other or not yet diagnosed
Step 2 of 7

What type of specialist are you looking for?

If you are unsure, choose the last option.

Medical oncologist
Hematologist-oncologist
Surgical oncologist
Radiation oncologist
Gynecologic oncologist
Neuro-oncologist
Pediatric oncologist
Multidisciplinary cancer team
I am not sure
Step 3 of 7

Why are you looking for an oncologist?

Choose the reason that best describes your current situation.

New diagnosis
Second opinion
Advanced or metastatic cancer
Treatment planning
Immunotherapy
Targeted therapy
Clinical trial
Cancer recurrence
Rare cancer
I am not sure
Step 4 of 7

How important is research or clinical-trial access?

This helps determine whether a research-oriented cancer center should receive greater priority.

Highest priority
Important
Somewhat important
Not important
Step 5 of 7

Where would you like to receive care?

Choose your geographic preference.

Prefer care near home
Prefer a major U.S. city
Anywhere in the U.S.
Will travel for a specialist
Step 6 of 7

What type of cancer center do you prefer?

Choose the type of center you would like to prioritize.

NCI-designated Comprehensive Cancer Center
Any NCI-designated cancer center
Academic or university cancer center
Major community cancer center
Any qualified cancer specialist
Step 7 of 7

What else should we consider?

Choose the additional factor that matters most to your search.

Insurance or network compatibility
International patient services
Telemedicine or remote second opinion
Rare or difficult-to-treat cancer
No additional preference
Please select an option before continuing.
Your search profile

Suggested oncology search pathway

Your answers indicate the type of specialist and cancer-center resources that may be useful to investigate.

1. Suggested specialist

2. Search NCI-designated cancer centers

NCI-designated cancer centers can be useful when specialized expertise, multidisciplinary care or clinical-trial access is important.

Search NCI-designated cancer centers

3. Verify physician certification

Before selecting a physician, verify the doctor's specialty certification and credentials through an established physician-certification resource.

Check ABMS physician certification

4. Search clinical trials

If clinical-trial access is relevant, search studies by cancer type, treatment and location.

Search ClinicalTrials.gov

5. Investigate cancer-center accreditation

The American College of Surgeons Commission on Cancer accredits cancer programs using standards covering cancer care and program quality.

Learn about ACS Commission on Cancer

6. Questions to ask an oncologist

  • How often do you treat this specific cancer?
  • Do you specialize in this cancer subtype?
  • What treatment options would you consider?
  • What biomarker or molecular tests are relevant?
  • Are there appropriate clinical trials?
  • Would a multidisciplinary tumor-board review be appropriate?
  • Would you recommend a second opinion?
  • How would the treatment plan change if the cancer progresses?

7. Prepare for a second opinion

Consider obtaining copies of your pathology report, imaging, laboratory results, operative reports and previous treatment records before the consultation.

If molecular or biomarker testing has already been performed, bring those reports as well.

Important: This selector does not diagnose cancer, rank individual oncologists or determine which treatment is medically appropriate. It is an educational search tool. Physician availability, credentials, insurance participation, cancer-specific expertise and appointment requirements should be independently verified.
About this tool: The selector is intended to help users organize their search for U.S. oncology care. NCI designation, accreditation or board certification does not by itself establish that a particular physician or center is the best choice for an individual patient.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated arti...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...
Read more

30 Best Alternative Cancer Treatments 2026: Proven Interventions

By Editorial Team
Image
Updated July 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—focu...
Read more

Fenbendazole, Ivermectin and Mebendazole for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Last updated: 15 July 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated July 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of July 2026. ...
Read more

Archive

Show more